Loading
A phase 3 trial of Flutamide, Goserelin / leuprolide and Leuprolide in Prostate cancer, run by Eastern Cooperative Oncology Group, completed.
Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer is a phase 3 interventional study registered as NCT00002881 by Eastern Cooperative Oncology Group, started 1996-10 and reaching its primary completion in 1998-04. Interventions recorded: flutamide, goserelin acetate, leuprolide acetate, suramin, therapeutic hydrocortisone, orchiectomy. Conditions recorded: Prostate Cancer.
Linked to the drug Flutamide because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Flutamide, Goserelin / leuprolide (ovarian function suppression), Leuprolide (leuprorelin) and GnRH agonists, Prostate cancer and the tag pipeline.
Shares Goserelin / leuprolide (ovarian function suppression), Leuprolide (leuprorelin) and GnRH agonists, ECOG-ACRIN Cancer Research Group, Prostate cancer and the tag pipeline.
Shares Flutamide, Goserelin / leuprolide (ovarian function suppression), Leuprolide (leuprorelin) and GnRH agonists, Prostate cancer and the tag pipeline.
Shares Flutamide, Goserelin / leuprolide (ovarian function suppression), Leuprolide (leuprorelin) and GnRH agonists, Prostate cancer and the tag pipeline.
Shares Flutamide, Prostate cancer and the tag pipeline.
Shares Flutamide, Goserelin / leuprolide (ovarian function suppression), Leuprolide (leuprorelin) and GnRH agonists, Prostate cancer and the tag pipeline.
Shares Flutamide, Goserelin / leuprolide (ovarian function suppression), Prostate cancer and the tag pipeline.
Shares Goserelin / leuprolide (ovarian function suppression), Prostate cancer and the tag pipeline.